论文部分内容阅读
吸收性高尿钙和肾性高尿钙是不同的两种病变类型,前者是肠钙吸收增加,而后者是肾小管钙重吸收功能受损。因此吸收性高尿钙选用纤维素磷酸钠以降低肠钙吸收,肾漏钙则以噻嗪类治疗。然而许多医师不愿花精力区分两者,凡是高尿钙病人均以噻嗪治疗。已有报告在2年期的治疗中,噻嗪能显著降低吸收性及肾性高尿钙的尿钙。但肠钙吸收在肾性高尿钙患者降低之际,在吸收性高钙患者仍然增高。为确定噻嗪对这两类高尿钙的长期效果,作者作了如下为期平均5.5年的研究。 12例吸收性高尿钙和10例肾性高尿钙患者,接受双氢克尿噻长期治疗(50mg,Bid)。治疗前,患者在恒定代谢饮食(400mg钙/天)3天后
Absorbable hypercalciuria and renal hyperuricemia are two different types of lesions, the former is an increase in intestinal calcium absorption, which is impaired renal tubular calcium reabsorption. Therefore, the use of high absorption of calcium phosphate sodium phosphate to reduce intestinal calcium absorption, renal leakage calcium is thiazide treatment. However, many physicians are reluctant to differentiate between the two, all with high urinary calcium patients treated with thiazide. It has been reported that in the 2-year treatment thiazide significantly reduces urinary calcium in absorption and renal hypercalciuria. However, intestinal calcium absorption decreased in patients with renal hyperuricaemia in patients with high absorption of calcium is still elevated. To determine the long-term effects of thiazide on these two types of hypercalciuria, the authors made the following an average of 5.5 years of research. Twelve patients with absorbable hypercalciuria and 10 patients with renal hyperuricemia were treated with long-term hydrochlorothiazide (50 mg, Bid). Patients were treated with a constant metabolic diet (400 mg calcium / day) 3 days prior to treatment